Based on the key indicators related to Revolution Medicines' liquidity, profitability, solvency, and operating efficiency, Revolution Medicines is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At present, Revolution Medicines' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 151 M, whereas Net Debt is projected to grow to (577.8 M). Key indicators impacting Revolution Medicines' financial strength include:
The essential information of the day-to-day investment outlook for Revolution Medicines includes many different criteria found on its balance sheet. An individual investor should monitor Revolution Medicines' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Revolution Medicines.
Net Income
(414.55 Million)
Revolution
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Other Non Cash Items
Issuance Of Capital Stock
Change To Inventory
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Net Working Capital
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Current Deferred Revenue
Net Receivables
Common Stock Total Equity
Inventory
Capital Stock
Short Term Debt
Intangible Assets
Short Term Investments
Deferred Long Term Liab
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Revolution Medicines Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Revolution Medicines' financial statements are interrelated, with each one affecting the others. For example, an increase in Revolution Medicines' assets may result in an increase in income on the income statement.
Please note, the presentation of Revolution Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revolution Medicines' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Revolution Medicines' management manipulating its earnings.
Revolution Medicines Stock Summary
Revolution Medicines competes with Blueprint Medicines, Sana Biotechnology, Kymera Therapeutics, Monte Rosa, and Black Diamond. Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Revolution Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 212 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Revolution Medicines's current stock value. Our valuation model uses many indicators to compare Revolution Medicines value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Revolution Medicines competition to find correlations between indicators driving Revolution Medicines's intrinsic value. More Info.
Revolution Medicines is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Revolution Medicines' Return On Equity is projected to increase based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Revolution Medicines by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Revolution Medicines Systematic Risk
Revolution Medicines' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Revolution Medicines volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Revolution Medicines correlated with the market. If Beta is less than 0 Revolution Medicines generally moves in the opposite direction as compared to the market. If Revolution Medicines Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Revolution Medicines is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Revolution Medicines is generally in the same direction as the market. If Beta > 1 Revolution Medicines moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Revolution Medicines Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Revolution Medicines' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Revolution Medicines growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.28)
At present, Revolution Medicines' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Revolution Medicines November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Revolution Medicines help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Revolution Medicines. We use our internally-developed statistical techniques to arrive at the intrinsic value of Revolution Medicines based on widely used predictive technical indicators. In general, we focus on analyzing Revolution Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Revolution Medicines's daily price indicators and compare them against related drivers.
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.